Related references
Note: Only part of the references are listed.Immunotherapeutic advancements for glioblastoma
Leonel Ampie et al.
FRONTIERS IN ONCOLOGY (2015)
Reliability of HSP70 (HSPA) expression as a prognostic marker in glioma
Glenda Maria Beaman et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2014)
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial
Orin Bloch et al.
NEURO-ONCOLOGY (2014)
Is there a role for vaccine-based therapy in recurrent glioblastoma?
Marc C. Chamberlain
NEURO-ONCOLOGY (2014)
Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccination for Recurrent Glioblastoma: A Phase II, Single Arm Trial
Orin Bloch et al.
NEURO-ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein
Courtney A. Crane et al.
CLINICAL CANCER RESEARCH (2013)
Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy
Robert M. Prins et al.
CLINICAL CANCER RESEARCH (2011)
Heat shock protein-peptide complex in the treatment of glioblastoma
Alfred P. See et al.
EXPERT REVIEW OF VACCINES (2011)
Vaccine provides new hope for patients with deadly brain cancer
[Anonymous]
FUTURE NEUROLOGY (2010)
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma
Sandeep Kunwar et al.
NEURO-ONCOLOGY (2010)
Glioblastoma-Derived Mechanisms of Systemic Immunosuppression
Allen Waziri
NEUROSURGERY CLINICS OF NORTH AMERICA (2010)
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
John H. Sampson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 study group
Alessandro Testori et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
An adjuvant autologous therapeutic vaccine (HSPPC-96 vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentrel, open-label, randomised phase III trial
Christopher Wood et al.
LANCET (2008)
The heat shock response and Chaperones/Heat shock proteins in brain tumors: Surface expression, release, and possible immune consequences
Michael W. Graner et al.
JOURNAL OF NEUROSCIENCE (2007)
A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma
Robert G. Maki et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy
E. Schmitt et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-hodgkin lymphoma
Yasuhiro Oki et al.
CANCER (2007)
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients
L Pilla et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses
S. Farzana Hussain et al.
NEURO-ONCOLOGY (2006)
Chaperone proteins and brain tumors: Potential targets and possible therapeutics
MW Graner et al.
NEURO-ONCOLOGY (2005)
Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications
DR Ciocca et al.
CELL STRESS & CHAPERONES (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Essential role of CD91 in re-presentation of gp96-chaperoned peptides
RJ Binder et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Pathways of chaperone-mediated protein folding in the cytosol
JC Young et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells
L Rivoltini et al.
JOURNAL OF IMMUNOLOGY (2003)
Phase III study of interferon Alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An eastern cooperative oncology group/intergroup trial
EM Messing et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes:: Clinical and immunologic findings
F Belli et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Cutting edge: CD91-independent cross-presentation of GRP94(gp96)-associated peptides
B Berwin et al.
JOURNAL OF IMMUNOLOGY (2002)
Heat shock proteins gp96 and hsp70 activate the release of nitric oxide by APCs
NN Panjwani et al.
JOURNAL OF IMMUNOLOGY (2002)
Roles of heat-shock proteins in innate and adaptive immunity
P Srivastava
NATURE REVIEWS IMMUNOLOGY (2002)
CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin
S Basu et al.
IMMUNITY (2001)
Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways
F Castellino et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Expression and functional activity of heat shock proteins in human glioblastoma multiforme
M Hermisson et al.
NEUROLOGY (2000)
Share Paper
